This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 May 14;135(20):1721-1722.

doi: 10.1182/blood.2020005364.

Ruxolitinib for steroid-resistant acute GVHD

Antonio Maria Risitano¹, Regis Peffault de Latour²

Affiliations

PMID: 32407526
DOI: 10.1182/blood.2020005364

Free article

Comment

Ruxolitinib for steroid-resistant acute GVHD

Antonio Maria Risitano et al. Blood. 2020.

Free article

. 2020 May 14;135(20):1721-1722.

doi: 10.1182/blood.2020005364.

Authors

Antonio Maria Risitano¹, Regis Peffault de Latour²

Affiliations

¹ Federico II University of Naples.
² Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris.

PMID: 32407526
DOI: 10.1182/blood.2020005364

No abstract available

PubMed Disclaimer

Comment on

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Jagasia M, et al. Blood. 2020 May 14;135(20):1739-1749. doi: 10.1182/blood.2020004823. Blood. 2020. PMID: 32160294 Free PMC article. Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems